U.S. Centers for Disease Control and Prevention, Atlanta, USA.
U.S. Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of the Congo.
Antiviral Res. 2019 Feb;162:171-177. doi: 10.1016/j.antiviral.2018.11.004. Epub 2018 Nov 14.
Healthcare-associated transmission of monkeypox has been observed on multiple occasions in areas where the disease is endemic. Data collected by the US Centers for Disease Control and Prevention (CDC) from an ongoing CDC-supported program of enhanced surveillance in the Tshuapa Province of the Democratic Republic of the Congo, where the annual incidence of human monkeypox is estimated to be 3.5-5/10,000, suggests that there is approximately one healthcare worker infection for every 100 confirmed monkeypox cases. Herein, we describe a study that commenced in February 2017, the intent of which is to evaluate the effectiveness, immunogenicity, and safety of a third-generation smallpox vaccine, IMVAMUNE, in healthcare personnel at risk of monkeypox virus (MPXV) infection. We describe procedures for documenting exposures to monkeypox virus infection in study participants, and outline lessons learned that may be of relevance for studies of other investigational medical countermeasures in hard to reach, under-resourced populations.
在猴痘流行地区，已经多次观察到与医疗保健相关的猴痘传播。美国疾病控制与预防中心（CDC）从刚果民主共和国 Tshuapa 省正在进行的 CDC 支持的强化监测计划中收集的数据表明，该省每年的人类猴痘发病率估计为每 10000 人中有 3.5-5 例，这表明每 100 例确诊的猴痘病例中约有 1 例医护人员感染。在此，我们描述了一项于 2017 年 2 月开始的研究，该研究旨在评估第三代天花疫苗 IMVAMUNE 对有感染猴痘病毒（MPXV）风险的医护人员的有效性、免疫原性和安全性。我们描述了记录研究参与者接触猴痘病毒感染的程序，并概述了可能对在难以到达、资源匮乏的人群中研究其他研究性医疗对策相关的经验教训。
